Replies to post #78453 on Biotech Values

[DewDiligence]

CSL will contest FTC opposition to Talecris buyout:

http://www.reuters.com/article/marketsNews/idINSYU00659620090527

Managing Director Brian McNamee said… U.S. regulators had failed to recognise that the deal would actually boost competition in the plasma products market…

I can’t imagine how it could do that.